Lantheus Stock Downgraded, Price Target Offers Upside Despite Challenges
Lantheus Holdings’ stock (NASDAQ: LNTH) is dealing with some analyst cuts, primarily stemming from performance concerns surrounding its key product, Pylarify. Recent downgrades, including one this morning, have impacted market sentiment, yet price target estimations continue to suggest a potential upside for the pharmaceutical company.
The stock is currently trading 2.6% lower in the pre-market session this morning. This price action reflects the market’s response to a series of revised outlooks from prominent financial institutions. The current price reflects investor apprehension as the company addresses headwinds.
Goldman Sachs downgraded Lantheus to “Neutral” from “Buy” today, setting a price target of $77, a reduction…
